Marije E Weidema
Overview
Explore the profile of Marije E Weidema including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
279
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tomassen T, Versleijen-Jonkers Y, Hillebrandt-Roeffen M, Van Cleef P, van Dalen T, Weidema M, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444414
Epithelioid hemangioendothelioma (EHE) is an extremely rare vascular sarcoma with variable aggressive clinical behavior. In this retrospective study, we aimed to investigate prognostic factors based on clinicopathologic findings in a...
2.
Versleijen-Jonkers Y, Hillebrandt-Roeffen M, Weidema M, Mooren J, von Rhein D, de Bitter T, et al.
Sci Rep
. 2023 Feb;
13(1):2653.
PMID: 36788310
Angiosarcomas are a heterogeneous group of rare endothelial malignancies with a complex, not completely unravelled biology. They encompass primary (sporadically occurring) angiosarcomas of several origins and secondary angiosarcomas, which often...
3.
van Ravensteijn S, Versleijen-Jonkers Y, Hillebrandt-Roeffen M, Weidema M, Nederkoorn M, Bol K, et al.
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497420
Angiosarcomas (AS) are extremely rare and aggressive vascular malignancies subdivided in de novo primary AS (pAS) and secondary AS (sAS). We hypothesize that the combination of immunological and genomic profiles...
4.
Weidema M, Desar I, Hillebrandt-Roeffen M, van Erp A, Masuzawa M, Flucke U, et al.
J Cancer Res Clin Oncol
. 2021 Jun;
147(9):2579-2590.
PMID: 34085099
Purpose: Angiosarcoma (AS) is a rare vasoformative sarcoma, with poor overall survival and a high need for novel treatment options. Clinically, AS consists of different subtypes, including AS related to...
5.
Koelsche C, Schrimpf D, Stichel D, Sill M, Sahm F, Reuss D, et al.
Nat Commun
. 2021 Jan;
12(1):498.
PMID: 33479225
Sarcomas are malignant soft tissue and bone tumours affecting adults, adolescents and children. They represent a morphologically heterogeneous class of tumours and some entities lack defining histopathological features. Therefore, the...
6.
Weidema M, Husson O, van der Graaf W, Leonard H, de Rooij B, Hartle DeYoung L, et al.
Acta Oncol
. 2020 Jun;
59(8):975-982.
PMID: 32476528
Epithelioid hemangioendothelioma (EHE) is an ultra-rare vascular sarcoma with unique clinical features. EHE is characterized by an unpredictable, often protracted, clinical course and highly variable clinical presentation. Due to difficulty...
7.
Weidema M, Flucke U, van der Graaf W, Ho V, Hillebrandt-Roeffen M, Versleijen-Jonkers Y, et al.
Cancers (Basel)
. 2019 Nov;
11(11).
PMID: 31726650
Angiosarcoma (AS) is a rare sarcoma of endothelial origin, arising spontaneously (primary AS) or after external damage such as radiation therapy or UV exposure (secondary AS). To date, reliable assessment...
8.
Weidema M, van de Geer E, Koelsche C, Desar I, Kemmeren P, Hillebrandt-Roeffen M, et al.
Clin Cancer Res
. 2019 Sep;
26(1):93-100.
PMID: 31562204
Purpose: DNA methylation profiling has previously uncovered biologically and clinically meaningful subgroups within many tumor types, but was not yet performed in angiosarcoma. Angiosarcoma is a rare sarcoma with very...
9.
van Erp A, Versleijen-Jonkers Y, Hillebrandt-Roeffen M, van Houdt L, Gorris M, van Dam L, et al.
Oncotarget
. 2017 Oct;
8(41):71371-71384.
PMID: 29050367
In order to explore the potential of immune checkpoint blockade in sarcoma, we investigated expression and clinical relevance of programmed cell death-1 (PD-1), programmed death ligand-1 (PD-L1) and CD8 in...